Stage IB NSCLC: no benefit for chemotherapy after complete resection

  • Lung Cancer

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Adjuvant chemotherapy (ACT) was not associated with improved OS or cancer-specific survival in patients with completely resected stage IB NSCLC, even in patients with larger tumors.

Why this matters

  • ACT is recommended for patients with resected stage II-III NSCLC, but guidelines offer competing recommendations in stage IB disease.

Study design

  • 1005 patients with completely resected stage IB (T2aN0M0) NSCLC.
  • Funding: None.

Key results

  • 20.1% (n=202) received ACT, with nearly 90% of those receiving ≥3 cycles.
  • After propensity matching of 196 patient pairs, ACT was not associated with improved OS (HR, 1.058; P=0.858), DFS (HR, 0.956; P=.845), cancer-specific OS (subHR, 1.000; P=1.000), or cancer-specific DFS (subHR, 0.920; P=.720).
  • After propensity matching, ACT was not associated with better OS, regardless of tumor size (tumors

Limitations

  • Retrospective study.
  • Chemotherapy regimens were not consistent.